209 related articles for article (PubMed ID: 21710357)
1. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
4. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
[TBL] [Abstract][Full Text] [Related]
5. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Haraoui B; Keystone EC; Thorne JC; Pope JE; Chen I; Asare CG; Leff JA
J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
[TBL] [Abstract][Full Text] [Related]
8. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
[TBL] [Abstract][Full Text] [Related]
10. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
11. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
Matsuno H
Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
13. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
16. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
Cuomo G; Molinaro G; La Montagna G; Migliaresi S; Valentini G
Reumatismo; 2006; 58(1):22-5. PubMed ID: 16639484
[TBL] [Abstract][Full Text] [Related]
17. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
Furst DE; Gaylis N; Bray V; Olech E; Yocum D; Ritter J; Weisman M; Wallace DJ; Crues J; Khanna D; Eckel G; Yeilding N; Callegari P; Visvanathan S; Rojas J; Hegedus R; George L; Mamun K; Gilmer K; Troum O
Ann Rheum Dis; 2007 Jul; 66(7):893-9. PubMed ID: 17412737
[TBL] [Abstract][Full Text] [Related]
18. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
20. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]